The IBD SmartSelect Composite Rating for Axogen increased from 92 to 97 Wednesday.
The new rating shows the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria. The best stocks tend to have a 95 or better grade as they kick off a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Axogen is now out of buy range after clearing the 15.25 buy point in a cup with handle.
Lean How — And When — To Sell Stocks
The stock earns an 81 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 81% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported 0% earnings growth for Q4. Sales growth came in at 15%, down from 18% in the previous quarter.
Axogen holds the No. 2 rank among its peers in the Medical-Products industry group. Boston Scientific is the No. 1-ranked stock within the group.
